Richard Pops serves as Chairman and Chief Executive Officer of Alkermes. He joined Alkermes as CEO in 1991. Under his leadership, Alkermes has grown from a privately held company with 25 employees to an international, publicly traded biopharmaceutical company with more than 2,000 employees. Alkermes has a diversified commercial product portfolio and a R&D pipeline focused on neuroscience and oncology. Mr. Pops currently serves on the Board of Directors of Neurocrine Biosciences, Epizyme, the Biotechnology Industry Organization (BIO) and the Pharmaceutical Research and Manufacturers of America (PhRMA).